Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women with Endometriosis

Ana Maria Sanchez, Raffaella Cioffi, Paola Viganò, Massimo Candiani, Roberta Verde, Fabiana Piscitelli, Vincenzo Di Marzo, Elisabetta Garavaglia, Paola Panina-Bordignon

Research output: Contribution to journalArticlepeer-review


Cannabinoids and modulators of the endocannabinoid system affect specific mechanisms that are critical to the establishment and development of endometriosis. The aim of this study was to measure the systemic levels of endocannabinoids and related mediators in women with and without endometriosis and to investigate whether such levels correlated with endometriosis-associated pain. Plasma and endometrial biopsies were obtained from women with a laparoscopic diagnosis of endometriosis (n = 27) and no endometrial pathology (n = 29). Plasma levels of endocannabinoids (N-arachidonoylethanolamine [AEA] and 2-arachidonoylglycerol [2-AG]) and related mediators (N-oleoylethanolamine [OEA] and N-palmitoylethanolamine [PEA]), messenger RNA expression of some of their receptors (cannabinoid receptor type 1 [CB1], CB2, transient receptor potential vanilloid type [TRPV1]), and the enzymes involved in the synthesis (N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D [NAPE-PLD]) and degradation (fatty acid amide hydrolase 1 [FAAH]) of AEA, OEA, and PEA were evaluated in endometrial stromal cells. The systemic levels of AEA, 2-AG, and OEA were elevated in endometriosis in the secretory phase compared to controls. The expression of CB1 was higher in secretory phase endometrial stromal cells of controls versus endometriosis. Similar expression levels of CB2, TRPV1, NAPE-PLD, and FAAH were detected in controls and endometriosis. Patients with moderate-to-severe dysmenorrhea and dyspareunia showed higher AEA and PEA levels than those with low-to-moderate pain symptoms, respectively. The association of increased circulating AEA and 2-AG with decreased local CB1 expression in endometriosis suggests a negative feedback loop regulation, which may impair the capability of these mediators to control pain. These preliminary data suggest that the pharmacological manipulation of the action or levels of these mediators may offer an alternative option for the management of endometriosis-associated pain.

Original languageEnglish
Pages (from-to)1071-1079
Number of pages9
JournalReproductive Sciences
Issue number8
Publication statusPublished - Aug 1 2016


  • endocannabinoids
  • endometriosis
  • pain

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women with Endometriosis'. Together they form a unique fingerprint.

Cite this